Skip to main content
OpenTrials
Completed

NCT Number: NCT06951204

Evaluation of the Role of Genicular Nerve Block When Combined With Adductor Canal Block for Pain Control Following Knee Arthroscopy

The intervention tests the efficacy of Genicular nerve block when combined with Adductor canal block in comparison with Adductor canal block alone to control post operative pain in knee arthroscopy

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ain Shams University

Cairo, Egypt, 11111

About this study

A. Preoperative settings:

All patients will be assessed preoperatively by careful history taking, full physical examination, and laboratory evaluation. An informed written consent will be taken from every patient just before the surgery.

Intraoperative and postoperative settings:

On arrival to the operating room, baseline parameters such as ECG, mean arterial blood pressure, heart rate, and oxygen saturation will be recorded. Intravenous line will be inserted, and IV Ringer's solution will be started, then induction of general anesthesia: Preoxygenation with 100% oxygen will be carried out for 2-3 minutes. Induction of anesthesia will be done using intravenous fentanyl 1-2 µg/kg and propofol 1-2 mg/kg. Endotracheal intubation will be facilitated with atracurium 0.4-0.5 mg/kg. Proper intubation will be confirmed by ETCO2 and bilateral auscultation of the chest. Anesthesia will be maintained with 60:40 oxygen mixed with air and isoflurane 1.2%. Lungs will be ventilated using volume-controlled ventilation with tidal volumes and respiratory rate adjusted to maintain end tidal CO2 at 35-40 MMGH.

After induction of general anesthesia and intubation:

Group A: • All patients will receive adductor canal block under complete aseptic conditions using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA ). while patient is laying supine lower limbs will slightly abducted at the hips and flexed at the knees , using linear ultrasound probe(2.5-7.5MHZ) on the anterior aspect of the patient's thigh, At the level of mid-thigh, by moving probe medially until the boat shaped Sartorius muscle is visualized , at which the adductor canal is identified beneath the sartorius muscle, a, 20ml bupivacaine (0.25%) will be injected in the canal after a careful negative aspiration. The spread of the drug lateral and around the femoral artery will be seen real time on ultrasound.

Group B: All patients will receive adductor canal block as described above under complete aseptic conditions then they will receive the genicular nerve block using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington, USA ), genicular nerve block will be done at three locations, i.e., superomedial, superolateral, and inferomedial locations of the condyle-shaft junction, while patient is lying supine linear ultrasound probe(2.5-7.5MHZ) will be used to target the superomedial, superolateral, and inferomedial genicular nerves, 2ml bupivacaine (0.25%) will be injected in the 3 mentioned points after a careful negative aspiration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Physical status: ASA 1 or 2 and candidates for knee arthroscopy.
  • Age group: 18-50 years.
  • No sex predilection.

Exclusion criteria

  • Physical status: ASA III or above.
  • Patients with a history of drug allergies to study drugs.
  • Previous trauma or surgery to the leg.
  • Opioids or alcohol abuse.
  • Bleeding tendency.
  • Dysesthesia, loss of sensation around the knee or medial aspect of the thigh.
  • Inability to cooperate.

Treatment and study plan

Adductor Canal Block (ACB) Only

Procedure

All patients will receive adductor canal block under complete aseptic conditions using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ). while patient is laying supine lower limbs will slightly abducted at the hips and flexed at the knees , using linear ultrasound probe(2.5-7.5MHZ) on the anterior aspect of the patient's thigh, At the level of mid-thigh, by moving probe medially until the boat shaped Sartorius muscle is visualized , at which the adductor canal is identified beneath the sartorius muscle, 20ml bupivacaine (0.25%) will be injected in the canal after a careful negative aspiration. The spread of the drug lateral and around the femoral artery will be seen real time on ultrasound

Adductor canal block (ACB) combined with Genicular nerve block (GNB)

Procedure

All patients will receive adductor canal block as described above under complete aseptic conditions then they will receive the genicular nerve block using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ), genicular nerve block will be done at three locations, i.e., superomedial, superolateral, and inferomedial locations of the condyle-shaft junction, while patient is lying supine linear ultrasound probe(2.5-7.5MHZ) will be used to target the superomedial, superolateral, and inferomedial genicular nerves,2ml bupivacaine (0.25%) will be injected in the 3 mentioned points after a careful negative aspiration

Primary outcomes

  1. post-operative pain after 6 hours after the time of administration of the block according to VAS score.

    Time frame: During 24 hours

    • To assess postoperative pain and its intensity a segmented numeric version of the visual analogue scale (VAS) is the score that used. The patient will select a whole number (0- 10 integers) that best reflects the intensity of his pain; 1-10 is recorded by a blinded investigator during 24 hours
    • All patients receive intravenous paracetamol IV/8 hours, Patients receive intravenous pethidine 0.5mg/kg as rescue analgesia when the VAS is equal or more than 4.

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Apr 30, 2025
Registry last updated
Apr 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.